

Variability in mRNA SARS-CoV-2 BNT162b2 vaccine immunogenicity is associated with differences in the gut microbiome and habitual dietary fibre intake

Genelle R. Healey¹, Liam Golding¹, Alana Schick¹, Abdelilah Majdoubi¹, Pascal M. Lavoie¹, Bruce A. Vallance^{1*}

¹BC Children's Hospital Research Institute, University of British Columbia, 950 West 28th Avenue, Vancouver, V5Z4H4, Canada

*Corresponding author: BC Children's Hospital Research Institute, University of British Columbia, 950 West 28th Avenue, Vancouver, V5Z 4H4, Canada. Phone: +1 604 875 2345 extension 5112. Email: bvallance@cw.bc.ca

Twitter: Genelle R Healey – @genellehealey, Alana Schick – @Alana_Schick, Abdelilah Majdoubi – @majdoubi_abdel, Pascal Lavoie – @Pascal_M_Lavoie, Bruce A Vallance – @brucevallance

Acknowledgements: We would like to take the opportunity to thank all the study participants for providing stool and blood samples and volunteering their time to our study. We would like to thank Lauren Muttucomoroe, Tisha Montgomery, Maria Laura Munoz and Azita Harriran for helping recruit and collect samples from participants, and the BC Children's Hospital Research Institute Gut4Health Microbiome Sequencing CORE and the University of British Columbia Sequencing and Bioinformatic Consortium for undertaking 16S rRNA sequencing. We also thank Mr. Roger Dyer for analyzing the stool short-chain fatty acids and the Weston Family Microbiome Initiative for providing the funding to undertake this study.

Contributions: GH, PL and BV conceived and designed the study. LG co-ordinated patient recruitment and assisted with blood sample processing with AM. LG undertook the vaccine response experimental

29 design, execution, and analyses. GH assembled stool collection kits, undertook the dietary fibre analysis,
30 and prepared stool samples for sequencing and short-chain fatty acid analysis. AS undertook the
31 statistical and bioinformatic analyses. GH wrote the manuscript with significant input from all co-
32 authors.

33
34 **Funding:** This study was funded by the Weston Family Microbiome Initiative (grant ID GR018179).

35
36 **Competing interests:** None to declare

37
38 **Ethics approval:** This study was approved by the University of British Columbia Clinical Research Ethics
39 Board (H20-01205).

40
41 **ORCID IDs:** Genelle Healey – <https://orcid.org/0000-0003-1418-2856>, Liam Golding –
42 <http://orcid.org/0000-0002-8851-8052>, Alana Schick – <http://orcid.org/0000-0001-7002-5711>, Abdelilah
43 Majdoubi – <http://orcid.org/0000-0002-2053-4793>, Pascal Lavoie – [http://orcid.org/0000-0002-2205-](http://orcid.org/0000-0002-2205-0362)
44 [0362](http://orcid.org/0000-0002-2205-0362), Bruce Vallance – <http://orcid.org/0000-0003-1345-6747>

45
46 **Word count:** 3995 (excluding abstract, figures, references etc.)

47 **ABSTRACT**

48 **Objective:** Little is known about the interplay between gut microbiome and SARS-CoV-2 vaccine
49 immunogenicity. In this prospective observational study, we investigated associations between
50 the gut microbiome, habitual dietary fibre intake, and mRNA vaccine-elicited immune
51 responses, including anti-Spike IgG, avidity, and ACE-2 competition (surrogate neutralization).

52 **Design:** 16S rRNA sequencing and short-chain fatty acid analyses were undertaken using stool
53 samples collected from 48 healthy individuals at baseline and twelve-weeks after 1st BNT162b2
54 SARS-CoV-2 vaccine dose. Associations between gut microbiome data and SARS-CoV-2 spike
55 and RBD IgG levels, competitive binding antibodies, and anti-SARS-CoV-2 spike total relative
56 fractional avidity assays were evaluated. A validated dietary fibre intake food frequency
57 questionnaire was also used to correlate habitual dietary fibre intakes with vaccine responses.

58 **Results:** Our data revealed several baseline bacterial taxa, including *Prevotella*, *Haemophilus*
59 and *Veillonella* ($p < 0.01$), associated with BNT162b2 vaccine responses. Several *Bacteroides* spp.
60 ($p < 0.01$) as well as *Bifidobacterium animalis*, ($p = 0.003$), amongst others, were positively
61 associated with antibody avidity. Conversely, concentrations of isovaleric and isobutyric acid
62 were higher in individuals with the lowest SARS-CoV-2 vaccine responses ($p < 0.01$). Classifying
63 participants based on habitual dietary fibre intake identified distinct avidity responses.

64 **Conclusion:** We showed associations between baseline gut microbiota composition and
65 immunogenicity of BNT162b2 vaccine responses, particularly avidity maturation. We also
66 demonstrate that branched-chain fatty acids and habitual dietary fibre intakes are associated
67 with BNT162b2 vaccine immunogenicity. Together these findings indicate a link between gut
68 microbiome, diet and antibody immunity to SARS-CoV-2 spike protein, suggesting interventions
69 which modulate the gut microbiome could enhance COVID-19 vaccine responses.

70 **SIGNIFICANCE OF THIS STUDY**

71 **What is already known on this subject?**

- 72 • Strength and persistence of the SARS-CoV-2 BNT162b2 vaccine is variable between
73 individuals.
- 74 • To date, only one study has demonstrated that baseline gut microbiota can predict
75 SARS-CoV-2 vaccine response.

76

77 **What are the new findings?**

- 78 • For the first time we showed that the higher concentrations of branched-chain fatty
79 acids, isovaleric and isobutyric acids, are negatively associated with SARS-CoV-2
80 BNT162b2 vaccine responses.
- 81 • We revealed that habitual dietary fibre intake led to variability in the strength of
82 antibody binding after the BNT162b2 vaccine. Specifically, high dietary fibre consumers
83 displayed a significant increase in antibody avidity between in their 1st and 2nd dose.

84

85 **How this study might affect research, practice, or policy**

- 86 • Our data suggests that therapeutic interventions which target the gut microbiome,
87 including dietary modification, as well as pre-, pro-, and post-biotics, could enhance
88 BNT162b2 vaccine immunogenicity, thus helping in the fight against COVID-19.

89 **INTRODUCTION**

90 A key strategy for controlling the COVID-19 pandemic is conferring robust and sustained
91 immunity via the administration of SARS-CoV-2 vaccines. Novel strategies to control the spread
92 of the SARS-CoV-2 virus and boost the immunogenicity of vaccines will prove helpful in the fight
93 against COVID-19. mRNA vaccines offer high efficacy in protecting against severe disease
94 caused by the wild-type strain and Omicron subvariants¹. However, antibody responses to FDA-
95 approved SARS-CoV-2 vaccines are extremely heterogeneous with some individuals failing to
96 mount high quality responses^{2,3}. Moreover, the vaccines do not provide sustained protection
97 against re-infection or symptomatic infection⁴. Therefore, it is important to understand the
98 factors influencing the immunogenicity of SARS-CoV-2 vaccines, including their capacity for
99 long-term protection.

100
101 Factors such as age, chronic disease, smoking, body mass index, depression, and stress have all
102 been implicated in vaccine responses, including those targeting SARS-CoV-2⁵⁻⁸. Interestingly,
103 the factors outlined above have also been shown to impact the gut microbiome. It is, therefore,
104 plausible that differences in gut microbiome profiles between individuals could contribute to
105 inter-individual variability in observed vaccine responses. Elucidating the role the gut
106 microbiome plays in SARS-CoV-2 vaccine immunogenicity offers the potential to screen for
107 potentially poor vaccine responders, as well as utilizing microbiome-targeted therapies, i.e.,
108 prebiotics, probiotics and postbiotics⁹, as adjuvants to enhance vaccine responses.

109
110 To date, only one publication has investigated potential associations between the gut
111 microbiome and SARS-CoV-2 vaccine immunogenicity⁸. Ng and colleagues associated
112 *Bifidobacterium adolescentis* with higher antibody responses after whole inactivated SARS-CoV-
113 2 CoronaVac vaccination. This study also found a positive association between neutralising
114 antibodies elicited by BNT162b2 vaccination and the presence of bacteria that express adhesive
115 surface structures such as flagella and fimbriae. While informative, additional research is clearly
116 needed to further elucidate the role that specific gut microbiota and associated metabolites
117 (i.e., short-chain fatty acids [SCFA]) play in the immunogenicity of SARS-CoV-2 vaccines.

118 In this study, we investigated the impact of habitual dietary fibre intakes, gut microbiome
119 signatures, and SCFAs, on mRNA (Pfizer-BioNTech BNT162b2) vaccine responses after the 1st
120 and 2nd doses.

121 **MATERIALS AND METHODS**

122 **Study cohort**

123 Uninfected healthcare workers aged ≥ 18 years were prospectively recruited at British Columbia
124 Children's Hospital (Vancouver, Canada) between February and August 2021 prior to receiving
125 two Pfizer-BioNtech BNT162b2 mRNA vaccine doses, approximately 4 months apart.
126 Participants who tested positive for SARS-CoV-2 by viral or Spike antibody testing of baseline
127 samples or nucleocapsid antibody testing of any sample were excluded. Blood samples were
128 collected at baseline (pre-vaccine), 12 weeks after 1st vaccination, and 4 weeks after 2nd Pfizer-
129 BioNtech BNT162b2 mRNA vaccination. Stool samples were collected at baseline and 12 weeks
130 after the 1st vaccine dose (**figure 1A**). This study was approved by the University of British
131 Columbia Clinical Research Ethics Board (H20-01205). Informed e-consent for collection of
132 blood and stool samples was obtained from all participants. Information on the participant
133 characteristic data collected can be found in the online supplementary information.

134

135 **Serum sample analyses**

136 ***SARS-CoV-2 spike and RBD IgG multiplex assay***

137 Anti-SARS-CoV-2 spike and receptor-binding domain (RBD)-specific antibodies were quantified
138 using a multiplexed electro-chemiluminescent assay (MSD, Rockville, MD)¹⁰. Details relating to
139 this assay can be found in the online supplementary information.

140

141 ***SARS-CoV-2 spike and RBD ACE-2 competition assay***

142 ACE-2 competitive binding (U/ml) was quantified using the same MSD multiplex assay as
143 described above. A detailed description of the method can be found in the online
144 supplementary information.

145

146 ***Anti-SARS-CoV-2 spike absolute and relative fractional avidity assay***

147 Anti-spike absolute and relative fractional avidities were determined using a modified version
148 of a previously described method^{11,12}. The full methodology can be found in the online
149 supplementary information.

150 **Stool collection**

151 Participants were provided with a stool sample collection kit and written instructions at their
152 initial and twelve-week post 1st BNT162b2 vaccine clinic visits. Details relating to how stool
153 samples were collected can be found in the online supplementary information.

154

155 **Short-chain fatty acid analysis**

156 Stool samples, collected in DNA Genotek ME-200 tubes (80-95% ethanol), were thawed on ice,
157 vortexed, and 700 µl was transferred to a Savant SPD131 DDA speedvac (Thermo Scientific)
158 centrifugal vacuum concentrator and run at room temperature until virtually all the ethanol
159 had evaporated. The samples were then processed as previously described in the online
160 supplementary information.

161

162 **16S rRNA sequencing**

163 The ThermoFisher MagMax microbiome nucleic acid ultra-isolation kit and semi-automated
164 Kingfisher Duo Prime were used to extract microbial DNA from the stool samples following the
165 manufacturer's instructions with minor modifications. 16S library preparation for individual
166 samples were performed at the BC Children's Hospital Research Institute Gut4Health
167 Microbiome Sequencing CORE, using a similar method to Kozich and colleagues¹³. Further
168 details relating to 16s rRNA sequencing can be found in the online supplementary information.

169

170 **Statistical analyses**

171 Refer to the online supplementary information for details relating to the statistical analyses
172 undertaken.

173 **RESULTS**

174 **Study cohort**

175 In total, 48 participants had a baseline stool sample collected and 41 had a sample collected at
176 twelve-weeks post 1st Pfizer-BioNTech BTN162b2 mRNA vaccine. Of these participants, 38 had
177 matching stool samples, and 37 and 18 had blood samples collected twelve-weeks post 1st and
178 4 weeks post 2nd BTN162b2 vaccine doses, respectively (**table S1, figure 1A**). The clinical
179 characteristics of the 48 participants are shown in **table S1**. Two additional participants (beyond
180 the 48) tested positive for SARS-CoV-2 during the study and were excluded from subsequent
181 analyses. One additional participant was also excluded as a possible SARS-CoV-2 misdiagnosis
182 indicated by a high RBD IgG level (**figure 1B**).

183

184 **Gut microbiome changes post 1st dose of BNT162b2 vaccine**

185 We undertook 16S rRNA sequencing on the 48 baseline and 41 twelve-week post 1st BTN162b2
186 vaccine stool samples. We generated on average 24.67 Mb (90,509 reads) of data per sample.
187 We also submitted 42 baseline and 37 twelve-week post 1st BTN162b2 vaccine stool samples
188 for SCFA analysis. Participant-specific antibiotic use as well as changes in weight and diet were
189 reported as these are common confounding factors in gut microbiota analyses (**table S1**). Only a
190 small number of participants reported taking antibiotics (n=3) or experiencing changes in
191 weight or diet (n=7). As the data from these participants were not considered outliers they
192 were included in subsequent analyses.

193

194 First, we compared the changes in gut microbiota alpha and beta diversity from baseline to
195 twelve weeks post 1st vaccine. There was a trend towards a reduction in Shannon alpha
196 diversity ($p=0.07812$; Wilcoxon) after the 1st vaccine dose (**figure 1C**). As well, a significant shift
197 ($p=0.0159$; PERMANOVA) in the gut microbiota community (i.e., beta diversity) was observed
198 from baseline to after the 1st dose (**figure 1D, figure S1A-C**). The specific microbes that were
199 changed after the 1st dose included a significant reduction in Actinobacteriota ($p<0.0001$,
200 $\log_2(\text{FoldChange}) = -0.672$; Wald test), *Anaerostipes* ($p=0.00161$, $\log_2(\text{FoldChange}) = -0.745$;
201 Wald test) and *Blautia* ($p=0.00103$, $\log_2(\text{FoldChange}) = -0.548$; Wald test) and an increase in

202 *Lachnospirillum* ($p=0.0018$, $\log_2(\text{FoldChange}) = -0.448$; Wald test) (**figure 2A**). A previous
203 study undertaken in a cohort in Hong Kong⁸ also demonstrated that the BNT162b2 vaccine led
204 to a significant reduction in Actinobacteriota and *Blautia* spp. Although significant changes in
205 several bacterial taxa were observed, no significant changes ($p>0.05$; Wilcoxon) in SCFAs were
206 shown after the 1st vaccine dose (**figure 2B**).

207

208 **Baseline gut microbiota and SCFAs impact immune response to BNT162b2 vaccination**

209 Ng and colleagues⁸ showed that specific baseline gut microbiota taxa impact immune responses
210 to the BNT162b2 vaccine. Therefore, we assessed each participants response to the 1st
211 BNT162b2 vaccine dose using relevant immune parameters including anti-RBD and spike IgG
212 levels, ACE-2 competitive binding antibody levels, and the anti-RBD and spike IgG to
213 competitive binding antibody ratio (measure of neutralizing capacity per antibody). Following
214 SARS-CoV-2 Spike mRNA vaccination many individuals develop antigen-specific B cells which
215 undergo class-switching and somatic hypermutation to produce IgG antibodies¹⁴. To assess the
216 relationship of the microbiome with immune outcomes, we selected parameters previously
217 shown to correlate with effective vaccine responses. Anti-Spike and anti-RBD IgG levels regulate
218 the magnitude of *in vitro* antibody-dependent functions such as complement deposition, Fc-
219 mediated cellular cytotoxicity and phagocytosis as well as live virus neutralization¹⁵⁻¹⁷. To
220 specifically measure the capacity to block RBD-ACE-2 binding, we performed a commercially
221 available *in vitro* anti-Spike and -RBD surrogate neutralization ACE-2 competition assay which
222 has been shown to strongly correlate with live virus neutralization¹⁸. To evaluate the potency or
223 the capacity of anti-Spike/RBD IgG to mediate ACE-2 blocking, we calculated a ratio of ACE-2
224 competitive binding antibodies by IgG for both Spike and RBD.

225

226 Variability in RBD IgG to competitive binding antibody ratio between participants was the
227 immune parameter most strongly associated ($p=0.07$; Wald test) with variation in the gut
228 microbiota (**figure 3A, figure S2A**). There were, however, specific taxa that were significantly
229 associated ($p<0.05$; Wald test) with several vaccine response parameters (**figure 3B, figure S2B-**
230 **C**). The most pronounced associations included a positive correlation between twelve-week

231 post 1st BNT162b2 vaccine RBD IgG levels and baseline *Prevotella* counts (p=0.032; Wald test)
232 (**figure 3C**) and negative correlations between post 1st vaccine RBD competitive binding
233 antibody levels and baseline *Clostridiales* bacterium DTU089 and CAG-352, and *Megasphaera*
234 counts (p=0.038, p=0.038 and p=0.047, respectively; Wald test) (**figure 3D, figure S2B**). Counts
235 of *Clostridiales* bacterium DTU089 at baseline were also negatively correlated with post 1st
236 vaccine spike competitive binding antibody levels (p=0.029; Wald test) (**figure 3E, figure S2C**).
237 Lastly, baseline Shannon and observed alpha diversity metrics were negatively correlated with
238 spike IgG (p=0.04, r= -0.3; Spearman rank) (**figure S3A**), and RBD competitive binding antibody
239 (p=0.035, r= -0.31; Spearman rank), RBD IgG (p=0.04, r= -0.3; Spearman rank), spike competitive
240 binding antibody (p=0.0077, r= -0.4; Spearman rank) and spike IgG (p=0.0073, r= -0.4; Spearman
241 rank), respectively (**figure S3B**).

242
243 As the functional capacity of the gut microbiome appears to be an important factor in
244 modulating immune responses¹⁹, we examined whether specific microbial metabolites
245 produced via bacterial fermentation, i.e., SCFAs, were associated with key immune parameters
246 post 1st BNT162b2 vaccine dose. The SCFAs acetate, propionate and butyrate exert anti-
247 inflammatory effects, whereas, relatively little is known about the impact that branched-chain
248 fatty acids (BCFA), such as isobutyric and isovaleric acids, have on immune responses¹⁹.
249 Baseline BCFA were negatively correlated with several immune parameters (**figure 4A**).
250 Specifically, higher baseline isovaleric acid concentrations (µmol/g stool) were negatively
251 associated with RBD IgG (p=0.0303, r= -0.373; Spearman rank) (**figure 4B**), spike IgG to
252 competitive binding antibody ratio (p=0.033, r= -0.367; Spearman rank) (**figure 4C**) and spike
253 IgG (p=0.0265, r= -0.381; Spearman rank) (**figure 4D**). Baseline isobutyric acid concentrations
254 were also negatively associated with spike IgG to competitive binding antibody ratio (p=0.0179,
255 r= -0.406; Spearman rank) (**figure 4C**).

256 257 **Baseline gut microbiota and SCFAs associated with responses to BNT162b2 vaccination**

258 As all participants developed a robust immune response to the 1st BNT162b2 vaccine dose, we
259 decided to group participants into quartiles, based on the strength of their response, to

260 determine whether there was a gut microbiota signature that differentiated between low and
261 high vaccine responders.

262

263 We observed a trend towards a distinctive gut microbiota signature between low (quartile 1)
264 and high vaccine responders (quartile 4) based on RBD IgG levels ($p=0.0554$; PERMANOVA)
265 (**figure 5A**). Correspondingly, there were also several baseline bacterial taxa that significantly
266 differed ($p<0.05$; Wald test) between participants with low versus high BNT162b2 vaccine
267 responses (**figure 5B, figure S4A-D**). The most pronounced bacterial taxa differences were
268 significantly higher baseline counts of *Prevotella* and *Haemophilus* genera in participants with
269 high RBD IgG levels ($p=0.00016$ and $p<0.0001$, respectively; Wald test) (**figure 5C, figure S4A**)
270 and RBD IgG to competitive binding antibody ratio ($p=0.0003$ and $p=0.0005$, respectively; Wald
271 test) (**figure 5D, figure S4B**). Participants with high RBD competitive binding antibody levels had
272 greater baseline counts of *Haemophilus* and *Veillonella* ($p=0.0043$ and $p<0.0001$, respectively;
273 Wald test) (**figure 5E, figure S4C**). Lastly, baseline *Prevotella* counts were also significantly
274 higher in participants with high spike IgG levels ($p=0.0054$; Wald test) (**figure 5F, figure S4D**).
275 Similar to the study by Ng and colleagues⁸, we also demonstrated that certain baseline gut
276 microbiota are associated with inter-individual responsiveness to the BNT162b2 vaccine. The
277 specific bacterial taxa did, however, differ between our two cohorts with their study identifying
278 that higher abundances of *Eubacterium rectale*, *Roseburia faces*, *Bacteroides thetaiotaomicron*
279 and *Bacteroides spp. OM05-12* were associated with stronger BNT162b2 vaccine responses.

280

281 In addition, we explored whether SCFAs were associated with varying BNT162b2 vaccine
282 responses. In our cohort, we observed significant differences in vaccine-dependent immune
283 responses in participants with distinctive baseline SCFA profiles; specifically, the BCFA
284 isobutyric and isovaleric acids. Participants with high baseline concentrations ($\mu\text{mol/g}$ stool) of
285 isobutyric acid had the lowest spike IgG to competitive binding antibody ratio ($p=0.045$; t-test,
286 Bonferroni corrected). Additionally, participants with high baseline concentrations of isovaleric
287 acid had the lowest RBD competitive binding antibody, RBD IgG and spike IgG levels ($p=0.021$,
288 $p=0.044$ and $p=0.042$, respectively; t-test, Bonferroni corrected) (**figure 5G, figure S5**).

289 **Anti-SARS-CoV-2 spike total relative fractional avidity was significantly associated with**
290 **several gut microbiota taxa but not SCFA concentrations**

291 IgG avidity maturation has been shown to modulate antibody-mediated functions and vaccine
292 effectiveness in a RTS,S/ AS01E malaria vaccine model and is known to evolve months following
293 SARS-CoV-2 mRNA vaccination²⁰⁻²². To circumvent the rigidity of traditional ELISA-based
294 chaotrope avidity assays we performed a multi-point titration of ammonium thiocyanate to
295 measure the quantity of very low to high avidity serum IgG by increasing concentrations of
296 chaotrope^{11,12}. Specifically, we assessed the avidity of BNT162b2 vaccine-elicited IgG to
297 determine whether the strength of antibody binding was associated with a specific gut
298 microbiome signature in the subset of participants in which blood was collected twelve weeks
299 after the 1st dose (timepoint V2) as well as four weeks after the 2nd vaccine dose (timepoint V3;
300 n=15). As expected, we found that the avidity at timepoint V3 was significantly higher than at
301 V2 (data not shown).

302
303 SCFA concentrations at baseline or twelve-weeks post 1st BNT162b2 vaccine dose were not
304 significantly associated with total relative fractional avidity (TRFA) (**figure S6**). However,
305 compositional features of the gut microbiota were significantly associated with TRFA after the
306 1st BNT162b2 vaccine dose (p=0.0438, r=0.094; Spearman rank; V2). Moreover, several bacterial
307 species were significantly correlated with TRFA after the 1st (V2) and 2nd (V3) BNT162b2 vaccine
308 dose. Specifically, higher TRFA after V2 was significantly associated with higher baseline
309 abundance of *Slackia isoflavoniconvertens*, *Phascolarctobacterium succinatutens*, *Howardella*
310 *ureilytica*, *Bacteroides plebeius*, *Bacteroides stercoris* and *Alistipes inops* (p<0.01; Wald test,
311 Benjamini-Hochberg adjusted) (**figure 6; table S2**). Additionally, lower baseline abundances of
312 *Sutterella wadsworthensis*, *Lachnospiraceae UCG-001 bacterium*, *Bacteroides coprocola* and
313 *Acidaminococcus intestini* (p<0.01; Wald test, Benjamini-Hochberg adjusted) were associated
314 with higher TRFA after V2 (**figure 6, table S2**).

315 After V3 there were several microbial species that were also positively associated with higher
316 TRFA including *Phascolarctobacterium succinatutens*, *Parabacteroides johnsonii*,
317 *Negativibacillus massilliensis*, *Megamonas funiformis*, *Eisenbergiella tayi*, *Desulfovibrio*

318 *fairfieldensis*, *Cloacibacillus evryensis*, *Bifidobacterium animalis*, *Bacteroides plebeius* and
319 *Bacteroides ovatus* ($p < 0.01$; Wald test, Benjamini-Hochberg adjusted) (**figure 6; table S3**).
320 Lastly, lower baseline abundances of *Bifidobacterium bifidum*, *Bacteroides massiliensis* and
321 *Acidaminococcus intestini* ($p < 0.0001$; Wald test, Benjamini-Hochberg adjusted) were associated
322 with higher TRFA after V3 (**figure 6; table S3**). These data suggest that a baseline gut microbiota
323 signature could predict the functional binding of BNT162b2 vaccine antibody responses
324 between individuals.

325
326 **Habitual dietary fibre intakes lead to differences in gut microbiota and total relative**
327 **fractional avidity to the BNT162b2 vaccine**

328 Previous studies have suggested that distinct habitual dietary intakes could lead to differing gut
329 microbiota responses to various therapies²³. No past research has elucidated whether habitual
330 dietary intakes, including fibre, impact SARS-CoV-2 vaccine responses via the gut microbiota.

331 Participants were classified as low (males < 22 g/day, females < 18 g/day), moderate (males 22
332 to 29.9 g/day, females 18 to 24.9 g/day), or high (males ≥ 30 g/day, females ≥ 25 g/day) dietary
333 fibre consumers using a validated habitual dietary fibre intake food frequency questionnaire²⁴.

334 There were trends towards a significant difference in microbial community structure between
335 low, moderate, and high dietary fibre consumers at baseline (**figure 7A**) and twelve-weeks post
336 1st dose (**figure 7A**) of the BNT162b2 vaccine ($p = 0.061$ and $p = 0.0558$, respectively;
337 PERMANOVA). Additionally, upon separating participants into low, moderate, and high dietary
338 fibre consumer groups we observed that the gut microbiome had shifted significantly by
339 twelve-weeks post 1st BNT162b2 vaccine dose in those individuals that were low dietary fibre
340 consumers ($p = 0.0332$; PERMANOVA) but a similar effect was not seen in moderate or high
341 dietary fibre consumers ($p = 0.511$ and $p = 0.517$, respectively; PERMANOVA) (**figure 7B**). Low
342 dietary fibre consumers may, therefore, be more prone to alterations in their gut microbiota
343 post BNT162b2 vaccination.

344
345 When comparing the association of differing habitual dietary fibre intakes with immune
346 response twelve weeks after the 1st BNT162b2 vaccine dose, high dietary fibre consumers

347 appeared to have lower TRFA compared to low and moderate dietary fibre consumers, though
348 this did not reach significance ($p=0.058$; Kruskal-Wallis, **figure 7C**). Interestingly, following the
349 2nd BTN162b2 dose TRFA values were more similar amongst the groups and less dependent on
350 dietary fibre intake. In addition, the increase in TRFA between doses was more pronounced in
351 high dietary fibre consumers ($p=0.018$; Kruskal-Wallis, **figure 7D**), suggesting that differing
352 habitual diets may impact the change in IgG binding strength.

353 **DISCUSSION**

354 Even though SARS-CoV-2 vaccines are highly effective, many vaccinated people still get infected
355 by SARS-Cov-2, with subpopulations developing severe disease²⁵. Generating sufficient
356 knowledge of the factors underlying COVID-19 vaccine immunogenicity is therefore important.
357 The multitude of microorganisms that reside within our gut are known to facilitate proper
358 development of the immune system, with an imbalance in gut microbiota, i.e., dysbiosis,
359 implicated in impaired immune responses²⁶. Recent studies also highlight the important
360 crosstalk that exists between the gut and lungs (gut-lung axis) in which the gut microbiome
361 plays a role in lung health and disease²⁷. Nevertheless, the impact of the microbiota on
362 immunity to SARS-CoV-2 vaccination remains poorly characterized. Here we examined the
363 influence baseline gut microbiota composition and function, as well as habitual dietary fibre
364 intakes, have on BNT162b2 vaccine immunogenicity. Utilizing 16S rRNA sequencing and GC-MS,
365 we profiled the gut microbiome at baseline and twelve weeks following the 1st BNT162b2 dose
366 to establish whether a gut microbiome signature was associated with enhanced vaccine
367 responses.

368
369 Participants were grouped as low or high vaccine responders to explore whether features of the
370 gut microbiome were associated with the degree of response. Higher baseline counts of
371 *Prevotella*, and *Haemophilus* were observed in participants with higher RBD IgG levels and RBD
372 IgG to competitive binding antibody ratio. Higher baseline counts of *Prevotella* were also shown
373 to be associated with higher spike IgG levels. Lastly, high counts of *Haemophilus* and *Veillonella*
374 were associated with higher RBD competitive binding antibody levels. Consistent with the
375 results from Ng and colleagues, baseline gut microbiota was also shown to be associated with
376 inter-individual responsiveness to the BNT162b2 vaccine⁸. The specific bacterial taxa that were
377 associated with BNT162b2 vaccine response differed between our two cohorts possibly due to
378 differences in geography (Hong Kong versus Canada), dietary habits and/or microbiome
379 sampling timepoint (1st versus 2nd BNT162b2 vaccine dose). In a study which investigated
380 whether exposure to non-infectious gut microbes shaped pre-existing immunity to SARS-CoV-2
381 in unexposed individuals, it was discovered that SARS-CoV-2 specific T cells can respond to non-

382 viral microbial peptides, defined cultured commensals (including *Prevotella* spp.) and undefined
383 fecal lysate²⁸. As a higher frequency of pre-existing SARS-CoV-2 T cells were associated with
384 milder disease and lower infection rates^{29,30} it is plausible that differences in commensal
385 microbe-based stimulation of SARS-CoV-2 specific immune cells prior to vaccination could
386 impact COVID-19 vaccine responses.

387
388 When assessing the antibody binding strength using an avidity assay, we also observed several
389 bacterial taxa that were associated with functional vaccine responses. No studies have
390 previously explored the impact the gut microbiome has on SARS-CoV-2 avidity, however several
391 of the microbes associated with avidity are known to have immunomodulatory properties.
392 Several *Bacteroides* species exhibited positive associations with TRFA in this cohort. Most
393 notably *Bacteroides ovatus* can induce increased production of IgM and IgG antibodies specific
394 to human cancer cells³¹ and can ameliorate lipopolysaccharide-induced inflammation in mice³².
395 Another bacterial species with known immune mediating effects, positively associated with
396 TRFA is *Bifidobacterium animalis*. Given as a probiotic *Bifidobacterium animalis* ssp. *lactis* can
397 significantly increase vaccine-specific IgG production after seasonal influenza vaccination³³.
398 Thus, bacterial species positively associated with TRFA could serve as adjuvants to enhance
399 vaccine immunogenicity to promote longer-term protective effects of the BNT162b2 vaccine.
400 However, this warrants further exploration in a larger cohort.

401
402 Another proposed mechanism linking the gut microbiota to vaccine responses is via SCFA
403 dependent B cell production of antibodies³⁴ and inhibition of histone deacetylases which
404 regulates the epigenetics of B cells¹⁹. Altered production of SCFAs, due to dysbiosis, has been
405 shown to disrupt immune responses during COVID-19 infection³⁵ suggesting that dysbiosis
406 could also disrupt SARS-CoV-2 vaccine responses. Isovaleric and isobutyric acids are BCFAs
407 which are synthesized exclusively from protein fermentation of branched-chain amino acids³⁶.
408 In our cohort, we observed higher isovaleric acid concentrations in participants with low RBD
409 competitive binding antibody, RBD IgG and spike IgG levels. Additionally, higher isobutyric acid
410 concentrations were associated with the lowest spike IgG to competitive binding antibody

411 ratios, suggesting a potentially negative role of BCFAs in vaccine responses. Conversely, other
412 SCFAs such as acetic, propionic, and butyric acids are produced from carbohydrate and protein
413 fermentation³⁷. High protein diets lead to higher concentrations of BCFAs, likely due to a shift
414 from carbohydrate to protein utilisation by the gut microbiota³⁸. BCFA concentrations have also
415 been shown to be higher in patients with immune-mediated conditions such as inflammatory
416 bowel disease³⁹. However, extremely little is known about the mechanisms by which BCFAs
417 modulate inflammatory processes or antibody-mediated vaccine responses. Interestingly,
418 *Megasphaera* spp., which in our study were also negatively associated with vaccine responses,
419 are prominent isovaleric and isobutyric acid producers⁴⁰. Strong conclusions cannot be drawn
420 from this novel observation, but it highlights the need for future research exploring the impact
421 that BCFAs, and BCFA-producing microbes have on SARS-CoV-2 vaccine responses.

422
423 Our study is the first to report an association between habitual dietary intakes and SARS-CoV-2
424 vaccine immunogenicity. Specifically, low habitual dietary fibre consumers experienced a more
425 pronounced shift in gut microbiota composition after receiving their 1st BNT162b2 vaccine
426 dose. Furthermore, high habitual dietary fibre consumers had lower TRFA after the 1st vaccine
427 dose but a significant increase from the 1st to 2nd dose which was not observed in low or
428 moderate habitual dietary fibre consumers. Unfortunately, stool was not collected after the 2nd
429 vaccine dose, so it is difficult to postulate whether the dramatic increase in TRFA in high
430 habitual dietary fibre consumers was also associated with differential alterations in the gut
431 microbiome as compared to low and moderate consumers. Significant changes in other host
432 responses, i.e., satiety, have been reported in high habitual dietary fibre consumers.
433 Interestingly, these more pronounced host responses were also associated with more
434 significant changes in the gut microbiota after a prebiotic intervention when compared to low
435 habitual dietary fibre consumers⁴¹. Although researchers have not focused on the effect
436 habitual diet has on vaccine responses, since diet is one of the main modifying factors of the
437 gut microbiota, it is certainly feasible that diet-dependent modulation of the gut microbiota
438 may alter vaccine immunogenicity. Protein deficient diets which lead to microbial dysbiosis can
439 reduce oral attenuated human rotavirus vaccine responses⁴² and dysbiosis in infants with

440 malnutrition has been correlated with lower efficacy of oral polio vaccines⁴³. Additionally,
441 specific nutraceutical deficiencies (i.e., vitamin C and D, omega-3s, zinc, selenium, and
442 magnesium) have been proposed to alter the gut microbiota and increase COVID-19 severity⁴⁴.
443 In contrast, the impact dietary fibres, which are fermented by resident microbiota to produce
444 SCFAs, have on COVID-19 severity or vaccine responses is unclear.

445
446 In summary, we demonstrate a link between the gut microbiome and individualized immune
447 responses to the BNT162b2 vaccine. In line with the Ng and colleagues' study, we observed that
448 several bacterial taxa were associated with altered vaccine responses, however, for the first
449 time this study also showed that BCFA levels may negatively impact vaccine responses, while
450 dietary factors, such as fibre intake, may modulate antibody maturation to mRNA vaccination.
451 Currently, there are several studies underway which aim to explore the therapeutic potential of
452 microbiome-targeted interventions in enhancing vaccine immunogenicity³⁵. Novel strategies
453 such as these are needed to help enhance and sustain SARS-CoV-2 vaccine responses.

454 **REFERENCES**

- 455 1. Patel R, Kaki M, Potluri VS, Kahar P, Khanna D. A comprehensive review of SARS-CoV-2
456 vaccines: Pfizer, Moderna & Johnson & Johnson. *Hum Vaccines Immunother.* 2022;18(1).
457 doi:10.1080/21645515.2021.2002083
- 458 2. Amodio E, Capra G, Casuccio A, et al. Antibodies responses to SARS-CoV-2 in a large
459 cohort of vaccinated subjects and seropositive patients. *Vaccines.* 2021;9(7).
460 doi:10.3390/vaccines9070714
- 461 3. Chivu-Economescu M, Bleotu C, Grancea C, et al. Kinetics and persistence of cellular and
462 humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without
463 prior COVID-19. *J Cell Mol Med.* 2022;26(4):1293-1305. doi:10.1111/jcmm.17186
- 464 4. Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Waning of SARS-CoV-2 booster viral-load
465 reduction effectiveness. *Nat Commun.* 2022;13(1):1-4. doi:10.1038/s41467-022-28936-y
- 466 5. Collier DA, Ferreira IATM, Kotagiri P, et al. Age-related immune response heterogeneity
467 to SARS-CoV-2 vaccine BNT162b2. *Nature.* 2021;596(7872):417-422.
468 doi:10.1038/s41586-021-03739-1
- 469 6. Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-
470 CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the
471 virus. *Am J Transplant.* 2021;21(8):2719-2726. doi:10.1111/ajt.16615
- 472 7. Madison AA, Shrout MR, Renna ME, Kiecolt-Glaser JK. Psychological and behavioral
473 predictors of vaccine efficacy: Considerations for COVID-19. *Perspect Psychol Sci.*
474 2021;16(2):191-203. doi:10.1177/1745691621989243
- 475 8. Ng SC, Peng Y, Zhang L, et al. Gut microbiota composition is associated with SARS-CoV-2
476 vaccine immunogenicity and adverse events. *Gut.* 2022;(January):gutjnl-2021-326563.
477 doi:10.1136/gutjnl-2021-326563
- 478 9. Frej-Mądrzak M, Jeziorek M, Sarowska J, Jama-Kmieciak A, Choroszy-Król I. The role of
479 probiotics and prebiotics in the proper functioning of gut microbiota and the treatment
480 of diseases caused by gut microbiota dysbiosis. *Nutr Obes Metab Surg.* 2020;7(1):9-15.
481 doi:10.5114/noms.2020.94667
- 482 10. Johnson M, Wagstaffe HR, Gilmour KC, et al. Evaluation of a novel multiplexed assay for

- 483 determining IgG levels and functional activity to SARS-CoV-2. *J Clin Virol.*
484 2020;130:104572. doi:10.1016/j.jcv.2020.104572
- 485 11. Abu Raya B, Bamberger E, Almog M, Peri R, Srugo I, Kessel A. Immunization of pregnant
486 women against pertussis: The effect of timing on antibody avidity. *Vaccine.*
487 2015;33(16):1948-1952. doi:10.1016/J.VACCINE.2015.02.059
- 488 12. Abu-Raya B, Giles ML, Kollmann TR, Sadarangani M. Profiling avidity of antibodies elicited
489 by vaccination using enzyme-linked immunosorbent assay-based elution – Insights into a
490 novel experimental and analytical approach. *Vaccine.* 2020;38(34):5389-5392.
491 doi:10.1016/j.vaccine.2020.06.060
- 492 13. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-
493 index sequencing strategy and curation pipeline for analyzing amplicon sequence data on
494 the miseq illumina sequencing platform. *Appl Environ Microbiol.* 2013;79(17):5112-5120.
495 doi:10.1128/AEM.01043-13
- 496 14. Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS-CoV-2. *Nat Rev*
497 *Immunol.* 2022;22(1):7-18. doi:10.1038/s41577-021-00657-1
- 498 15. Bartsch YC, Fischinger S, Siddiqui SM, et al. Discrete SARS-CoV-2 antibody titers track
499 with functional humoral stability. *Nat Commun* 2021 121. 2021;12(1):1-8.
500 doi:10.1038/s41467-021-21336-8
- 501 16. Thomas AS, Coote C, Moreau Y, et al. Antibody-dependent cellular cytotoxicity responses
502 and susceptibility influence HIV-1 mother-to-child transmission. *JCI Insight.* 2022;7(9).
503 doi:10.1172/JCI.INSIGHT.159435
- 504 17. Jarlhelt I, Nielsen SK, Jahn CXH, et al. SARS-CoV-2 Antibodies Mediate Complement and
505 Cellular Driven Inflammation. *Front Immunol.* 2021;12:4612.
506 doi:10.3389/FIMMU.2021.767981/BIBTEX
- 507 18. Sancilio A, D'aquila R, McNally EM, et al. A surrogate virus neutralization test to quantify
508 antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples.
509 *medRxiv.* February 2021:2021.02.14.21251709. doi:10.1101/2021.02.14.21251709
- 510 19. Yao Y, Cai X, Fei W, Ye Y, Zhao M, Zheng C. The role of short-chain fatty acids in
511 immunity, inflammation and metabolism. *Crit Rev Food Sci Nutr.* 2022;62(1):1-12.

- 512 doi:10.1080/10408398.2020.1854675
- 513 20. Tauzin A, Gong SY, Beaudoin-Bussi eres G, et al. Strong humoral immune responses
514 against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval
515 between doses. *Cell Host Microbe*. December 2021. doi:10.1016/J.CHOM.2021.12.004
- 516 21. Doba o C, Sanz H, Sorgho H, et al. Concentration and avidity of antibodies to different
517 circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. *Nat*
518 *Commun* 2019 101. 2019;10(1):1-13. doi:10.1038/s41467-019-10195-z
- 519 22. Thompson HA, Hogan AB, Walker PGT, et al. Modelling the roles of antibody titre and
520 avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01
521 vaccination. *Vaccine*. 2020;38(47):7498-7507. doi:10.1016/J.VACCINE.2020.09.069
- 522 23. Healey GR, Murphy R, Brough L, Butts CA, Coad J. Interindividual variability in gut
523 microbiota and host response to dietary interventions. *Nutr Rev*. 2017;75(12):1059-1080.
524 doi:10.1093/nutrit/nux062
- 525 24. Healey G, Brough L, Murphy R, Hedderley D, Butts C, Coad J. Validity and reproducibility
526 of a habitual dietary fibre intake short food frequency questionnaire. *Nutrients*.
527 2016;8(9):3-9. doi:10.3390/nu8090558
- 528 25. Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and
529 COVID-19 hospitalization and disease severity. *J Am Med Assoc*. 2021;326(20):2043-
530 2054. doi:10.1001/jama.2021.19499
- 531 26. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and
532 disease. *Cell Res*. 2020;30(6):492-506. doi:10.1038/s41422-020-0332-7
- 533 27. Dang AT, Marsland BJ. Microbes, metabolites, and the gut–lung axis. *Mucosal Immunol*.
534 2019;12(4):843-850. doi:10.1038/s41385-019-0160-6
- 535 28. Bartolo L, Afroz S, Pan Y-G, et al. SARS-CoV-2-specific T cells in unexposed adults display
536 broad trafficking potential and cross-react with commensal antigens. *Sci Immunol*.
537 2022;3:127.
538 [https://www.biorxiv.org/content/10.1101/2021.11.29.470421v1%0Ahttps://www.biorxi](https://www.biorxiv.org/content/10.1101/2021.11.29.470421v1%0Ahttps://www.biorxiv.org/content/10.1101/2021.11.29.470421v1.abstract)
539 [v.org/content/10.1101/2021.11.29.470421v1.abstract](https://www.biorxiv.org/content/10.1101/2021.11.29.470421v1.abstract).
- 540 29. Mallajosyula V, Ganjavi C, Chakraborty S, et al. CD8+T cells specific for conserved

- 541 coronavirus epitopes correlate with milder disease in COVID-19 patients. *Sci Immunol.*
542 2021;6(61). doi:10.1126/sciimmunol.abg5669
- 543 30. Swadling L, Diniz MO, Schmidt NM, et al. *Pre-Existing Polymerase-Specific T Cells Expand*
544 *in Abortive Seronegative SARS-CoV-2*. Vol 601.; 2021. doi:10.1038/s41586-021-04186-8
- 545 31. Ulsemer P, Henderson G, Toutounian K, et al. Specific humoral immune response to the
546 Thomsen-Friedenreich tumor antigen (CD176) in mice after vaccination with the
547 commensal bacterium *Bacteroides ovatus* D-6. *Cancer Immunol Immunother.*
548 2013;62(5):875-887. doi:10.1007/s00262-013-1394-x
- 549 32. Tan H, Zhao J, Zhang H, Zhai Q, Chen W. Novel strains of *Bacteroides fragilis* and
550 *Bacteroides ovatus* alleviate the LPS-induced inflammation in mice. *Appl Microbiol*
551 *Biotechnol.* 2019;103(5):2353-2365. doi:10.1007/s00253-019-09617-1
- 552 33. Rizzardini G, Eskesen D, Calder PC, Capetti A, Jespersen L, Clerici M. Evaluation of the
553 immune benefits of two probiotic strains *Bifidobacterium animalis* ssp. *lactis*, BB-12[®]
554 and *Lactobacillus paracasei* ssp. *paracasei*, *L. casei* 431[®] in an influenza vaccination
555 model: A randomised, double-blind, placebo-controlled study. *Br J Nutr.*
556 2012;107(6):876-884. doi:10.1017/S000711451100420X
- 557 34. Yamamoto I, Adachi T, Kishiro Y, Fujiwara M, Gohda E. Interleukin-2 - dependent
558 augmentation of the anti-tnp antibody production by sodium butyrate in cultured murine
559 splenic B cells. *Int J Immunopharmacol.* 1997;19(6):347-354.
- 560 35. Chen J, Vitetta L, Henson JD, Hall S. The intestinal microbiota and improving the efficacy
561 of COVID-19 vaccinations. *J Funct Foods.* 2021;87:104850. doi:10.1016/j.jff.2021.104850
- 562 36. Smith EA, Macfarlane GT. Dissimilatory amino acid metabolism in human colonic
563 bacteria. *Anaerobe.* 1997;3(5):327-337. doi:10.1006/anae.1997.0121
- 564 37. Gilbert MS, Ijssennagger N, Kies AK, van Mil SWC. Protein fermentation in the gut;
565 implications for intestinal dysfunction in humans, pigs, and poultry. *Am J Physiol -*
566 *Gastrointest Liver Physiol.* 2018;315(2):G159-G170. doi:10.1152/ajpgi.00319.2017
- 567 38. Russell WR, Gratz SW, Duncan SH, et al. High-protein, reduced-carbohydrate weight-loss
568 diets promote metabolite profiles likely to be detrimental to colonic health. *Am J Clin*
569 *Nutr.* 2011;93(5):1062-1072. doi:10.3945/ajcn.110.002188

- 570 39. Van Nuenen MHMC, Venema K, Van Der Woude JCJ, Kuipers EJ. The metabolic activity of
571 fecal microbiota from healthy individuals and patients with inflammatory bowel disease.
572 *Dig Dis Sci.* 2004;49(3):485-491. doi:10.1023/B:DDAS.0000020508.64440.73
- 573 40. Dai Z, Wu G, Zhu W. Amino acid metabolism in intestinal bacteria: links between gut
574 ecology and host health. *Front Biosci.* 2011;16:1768-1786.
575 doi:10.1109/leoswt.2008.4444364
- 576 41. Healey G, Murphy R, Butts C, Brough L, Whelan K, Coad J. Habitual dietary fibre intake
577 influences gut microbiota response to an inulin-type fructan prebiotic: a randomised,
578 double-blind, placebo-controlled, cross-over, human intervention study. *Br J Nutr.* 2018.
579 doi:10.1017/S0007114517003440
- 580 42. Kumar A, Vlasova AN, Deblais L, et al. Impact of nutrition and rotavirus infection on the
581 infant gut microbiota in a humanized pig model. *BMC Gastroenterol.* 2018;18(1):1-17.
582 doi:10.1186/s12876-018-0810-2
- 583 43. Haque R, Snider C, Liu Y, et al. Oral polio vaccine response in breast fed infants with
584 malnutrition and diarrhea. *Vaccine.* 2014;32(4):478-482.
585 doi:10.1016/j.vaccine.2013.11.056
- 586 44. Rishi P, Thakur K, Vij S, et al. Diet, gut microbiota and COVID-19. *Indian J Microbiol.*
587 2020;60(4):420-429. doi:10.1007/s12088-020-00908-0
588

Figures




Figure 1 Participant flow through the study, COVID-19 diagnosis and changes in alpha and beta diversity from baseline to twelve-weeks post 1st BNT162b2 vaccine. (A) Study design and sample collection. (B) Three participants were excluded from the analyses as two participants indicated a positive SARS-CoV-2 test during the study and one participant may have had a missed COVID-19 diagnosis due to a high RBD IgG level. (C) A trend towards a significant reduction in Shannon alpha diversity was observed ($p=0.07812$; Wilcoxon rank test). (D) A significant shift in beta diversity occurred between baseline and post 1st BNT162b2 vaccine ($p=0.0159$; PERMANOVA).




Figure 2 Change in specific taxonomy and SCFA production from baseline to twelve-weeks post 1st BTN162b2 vaccine. (A) A significant reduction in Actinobacteriota ($p < 0.0001$), *Anaerostipes* ($p = 0.00161$) and *Blautia* ($p = 0.00103$) an increase in *Lachnoclostridium* ($p = 0.00179$) were observed after the 1st BNT162b2 vaccine. (B) No significant changes ($p > 0.05$) in SCFAs were observed after the 1st BNT162b2 vaccine. P-values determined using Wald test of significance.




Figure 3 Correlation between baseline gut microbiota taxa and immune parameters twelve-weeks post 1st BNT162b2 vaccine. (A) The variability in RBD and spike IgG, competitive binding antibody and IgG to competitive binding antibody ratio explained by the variability in gut microbiota composition (PERMANOVA). (B) Heat-map of the gut microbiota taxa positively (red) or negatively (blue) correlated with each of the immune parameters (*p<0.05; Wald test). (C) Baseline *Prevotella* counts were positively associated with RBD IgG levels post 1st BNT162b2 vaccine (p=0.032; Wald test). (D) Baseline *Clostridiales* bacterium DTU089 and CAG-352, and *Megasphaera* counts were negatively associated with RBD competitive binding antibody levels post 1st BNT162b2 vaccine (p=0.038, p=0.038 and p=0.047, respectively; Wald test). (E) Baseline *Clostridiales* bacterium DTU089 counts were negatively associated with spike competitive binding antibody levels post 1st BNT162b2 vaccine (p=0.029; Wald test).




Figure 4 Correlation between baseline SCFA and immune parameters twelve-weeks post 1st BNT162b2 vaccine. (A) Heat-map of the specific SCFAs that were negatively (blue) or positively (yellow) correlated with each of the immune response parameters (* $p < 0.05$; Spearman rank). (B) Baseline isovaleric acid concentrations were negatively associated with RBD IgG levels ($p = 0.0303$, $r = -0.373$; Spearman rank). (C) Baseline isobutyric and isovaleric acid concentrations were negatively associated with spike IgG to competitive binding antibody ratio levels ($p = 0.0179$, $r = -0.406$ and $p = 0.033$, $r = -0.367$, respectively; Spearman rank). (D) Baseline isovaleric acid concentrations were negatively associated with spike IgG levels ($p = 0.0265$, $r = -0.381$; Spearman rank).




Figure 5 Significant differences in baseline microbial taxa in participants with differential (lowest [quartile 1] versus highest [quartile 4]) immune parameter responses twelve-weeks post 1st BNT162b2 vaccine. (A) A trend towards a significant difference ($p=0.0554$; PERMANOVA) in the gut microbiota community was observed in participants with the lowest (quartile 1 [pink]) versus the highest (quartile 4 [green]) RBD IgG response twelve-weeks post 1st BNT162b2 vaccine dose. (B) Heat-map depicting several significantly higher (red) or lower (blue) ($*p<0.05$; Wald test) baseline microbial counts in high (quartile 4) versus low (quartile 1) BNT162b2 vaccine responders across several immune parameters. (C) Baseline *Prevotella* and *Haemophilus* counts were significantly ($p=0.00016$ and $p<0.0001$, respectively; Wald test) higher in participants with the highest (quartile 4) RBD IgG levels twelve-weeks post 1st BNT162b2 vaccine. (D) Baseline *Prevotella* and *Haemophilus* counts were significantly ($p=0.00029$ and $p=0.00049$, respectively; Wald test) higher in participants with the highest (quartile 4) ratio of RBD IgG to competitive binding antibody levels twelve-weeks post 1st BNT162b2 vaccine. (E) Baseline *Haemophilus* and *Veillonella* counts were significantly ($p=0.0043$ and $p<0.0001$, respectively; Wald test) higher in participants with the highest (quartile 4) RBD competitive binding antibody levels twelve-weeks post 1st BNT162b2 vaccine. (F) Baseline *Prevotella* counts were significantly ($p=0.00544$; Wald

test) higher in participants with the highest (quartile 4) ratio of RBD IgG to competitive binding antibody twelve-weeks post 1st BNT162b2 vaccine. (G) Individuals with the highest baseline concentrations ($\mu\text{mol/g}$ stool) of isobutyric acid had the lowest spike IgG to competitive binding antibody ratio levels ($p=0.045$; t-test, Bonferroni corrected) while those with the highest baseline concentrations of isovaleric acid had the lowest RBD competitive binding antibody, RBD IgG and spike IgG levels ($p=0.021$, $p=0.044$ and $p=0.042$, respectively; t-test, Bonferroni corrected).




Figure 6 Significant associations between certain microbial species and total relative fractional avidity (TRFA). Several gut microbiota species were significantly positively or negatively associated ($p<0.01$; Wald test) with higher avidity after the 1st dose of the BNT162b2 vaccine (V2) in a subset of participants ($n=15$). Several gut microbiota species were also significantly positively or negatively associated ($p<0.01$; Wald test) with higher avidity after the 2nd dose of the BNT162b2 vaccine (V3) in a subset of participants ($n=15$). Refer to table 3 and 4 for the specific species names and p values.







Figure 7 Differences in the gut microbiota community between low, moderate, and high habitual dietary fibre consumers at baseline and twelve-weeks post 1st dose of the BNT162b2 vaccine. (A) At baseline, differing habitual dietary fibre intakes led to a trend towards significant differences ($p=0.061$; PERMANOVA) in the structure of the gut microbiota community. Twelve-weeks post 1st dose of the BNT162b2 vaccine differing habitual dietary fibre intakes led to a trend towards significant differences ($p=0.0558$; PERMANOVA) in the structure of the gut microbiota community. (B) A significant shift in the gut microbiota was revealed in low ($p=0.0332$; PERMANOVA) but not moderate and high dietary fibre consumers ($p=0.511$ and $p=0.517$, respectively; PERMANOVA) twelve-weeks after the 1st dose of the BNT162b2 vaccine. (C) After the 1st dose of the BNT162b2 vaccine TRFA was lower in high dietary fibre consumers but not significantly ($p=0.058$; Kruskal-Wallis). (D) High dietary fibre consumers had a significantly ($p=0.018$; Kruskal-Wallis) greater change in TRFA from the 1st to 2nd BNT162b2 dose compared to low and moderate dietary fibre consumers.

A**B****C****D**